← Back

Wire · regulatory

Inovio's Voceryq wins accelerated approval as first plasmid DNA immunotherapy

Published

2 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 3 November 2026 · Fusion42 review

The US FDA granted accelerated approval to INOVIO Pharmaceuticals' Voceryq, the first plasmid DNA-based immunotherapy, for reducing surgical frequency in adults with recurrent respiratory papillomatosis. The approval sets a regulatory precedent for plasmid DNA medicines and is contingent on a confirmatory trial to verify clinical benefit.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

FDA's green light on plasmid DNA treatment opens a new pathway for DNA-based drugs in US biotech. You need to consider plasmid platforms as viable alternatives to viral or lipid carriers in clinical development.

◆ Coverage

9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaldna-immunotherapyplasmid-dnarrp-treatmentinovio